XYZAL ALLERGY 24HR (levocetirizine dihydrochloride) by Sanofi is levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of h 1 receptors. First approved in 2017.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
XYZAL ALLERGY 24HR is an oral solution containing levocetirizine dihydrochloride, the active S-enantiomer of cetirizine, used to treat allergic rhinitis and urticaria symptoms. It works by selectively inhibiting H1 receptors, demonstrating 2-fold higher receptor affinity than racemic cetirizine. The 24-hour formulation provides extended symptomatic relief with once-daily dosing.
Product faces near-term loss of exclusivity (October 2027) in a crowded OTC allergy market with 15 documented competitors, likely requiring defensive positioning and reduced team investments.
Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Worked on XYZAL ALLERGY 24HR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Working on XYZAL ALLERGY 24HR offers limited career growth given the product's imminent loss of exclusivity and mature OTC market position. Roles on this asset typically emphasize defensive sales execution, account management, and operational efficiency rather than brand-building or innovation—making it better suited as a stabilizing interim assignment or for professionals seeking less demanding work environments.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo